LEADER 01538nam0-22004331i-450- 001 990006439400403321 005 20110218113133.0 010 $a88-205-0614-9 010 $a88-205-0646-7 010 $a88-205-0683-1 010 $a88-205-0715-3 035 $a000643940 035 $aFED01000643940 035 $a(Aleph)000643940FED01 035 $a000643940 100 $a20010328g19881994km-y0itay50------ba 101 0 $alat 102 $aIT 105 $a----c---001yy 200 1 $aIndex modo et ratione ordinatus$eoperum ad ius romanum pertinentium quae inde ab anno 1971 usque ad annum 1980 edita sunt$fcuravit Manlius Sargenti$gadiuvantibus G. Luraschi, M.P. Piazza, Fl. Barberis 210 $aMediolani$cCisalpino-Goliardica$d1988-1994 215 $a4 v.$d25 cm 304 $aSul front.: Alma Ticinensis Universitas. Institutum Iuris Romani et Historiae Iuris 327 1 $a1.: A-H. - 1988$a2.: I-M. - 1989$a3.: N-Z. - 1990$a4.: addenda et corrigenda materiae et auctores qui in indice continentur. - 1994 676 $a013$v20$zit 702 1$aSargenti,$bManlio 702 1$aLuraschi,$bGiorgio 702 1$aPiazza,$bMaria Pia 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990006439400403321 952 $aBIBL. I 51 (1-4)$b2224 (1-3) ddr; 2542 ddr$fDDR 952 $aBIBL. I 1 (1)$b744$fNAP02 952 $aBIBL. I 1 (2)$b745$fNAP02 952 $aBIBL. I 1 (3)$b746$fNAP02 959 $aDDR 959 $aNAP02 996 $aIndex modo et ratione ordinatus$9607897 997 $aUNINA LEADER 04971nam 2201249z- 450 001 9910557148103321 005 20210501 035 $a(CKB)5400000000040577 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/68388 035 $a(oapen)doab68388 035 $a(EXLCZ)995400000000040577 100 $a20202105d2021 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aMetabolism and Metabolomics of Liver in Health and Disease 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021 215 $a1 online resource (268 p.) 311 08$a3-03943-635-X 311 08$a3-03943-636-8 330 $aWomen and men have probably never been concerned as much by their health as during this COVID-19 pandemic. In this context, lifestyle habits continue to be promoted as allies for daily prevention against diseases. This is valid also for metabolic diseases, among which many affect the liver and are risk factors for aggravating the disease course of COVID-19. In fact, liver diseases are currently a major global health problem. There is a huge range of liver diseases and non-alcoholic fatty liver disease (NAFLD) is the most common chronic hepatic condition, which in some patients progresses to cirrhosis and liver cancer. Currently, substantial efforts are being made to better understand NAFLD, especially, because there is no U.S. Food and Drug Administration (FDA)-approved pharmacological therapy. To explore this disease, metabolomics is the most recently developed omics technology after genomics, transcriptomics, and proteomics. Metabolomics is the large-scale analysis of molecules, known as metabolites that are intermediate or end products of metabolism found within cells, tissues, and biofluids. This technology has a very high potential to identify biomarker candidates for the future development of new therapeutics. The book features articles that address metabolomics technology and its use to document different liver functions and dysfunctions, with a major focus on NAFLD. 606 $aMedicine and Nursing$2bicssc 610 $a1H-NMR spectroscopy 610 $aacetaminophen 610 $aacupuncture 610 $aalcoholic liver disease 610 $aarachidonic acid 610 $abile acids 610 $abiomarker 610 $ablood 610 $acarbohydrate response element-binding protein 610 $acells 610 $acholestasis 610 $aChREBP 610 $acirrhosis 610 $ade novo lipogenesis 610 $adiabetes 610 $adocosahexaenoic acid 610 $afeces 610 $afibrosis 610 $aFibrosis 610 $aGC-MS 610 $aGenomics 610 $aglucose homeostasis 610 $aglucose production 610 $aglycogen 610 $aglycogen storage disease type I 610 $aglycolysis 610 $aheat stress 610 $aHepaRG 610 $ahepatotoxicity 610 $ahexosamine 610 $aimflammation 610 $ain vitro 610 $ainflammation 610 $alipid homeostasis 610 $alipid metabolism 610 $alipidomics 610 $aliquid chromatography 610 $aliquid chromatography-mass spectrometry 610 $aliver 610 $aLiver biopsy 610 $aliver function 610 $amass spectrometry 610 $ametabolic pathway 610 $ametabolic profile 610 $ametabolic stress 610 $ametabolomics 610 $aMetabolomics 610 $ametabolomics quantitative profiling 610 $amultivariate statistical analysis 610 $aNAFL 610 $aNAFLD 610 $aNASH 610 $anicotinamide 610 $anon-alcoholic fatty liver disease 610 $anon-alcoholic steatohepatitis 610 $anonalcoholic fatty liver 610 $anonalcoholic fatty liver disease 610 $anonalcoholic steatohepatitis 610 $anuclear magnetic resonance spectroscopy 610 $aoxidative stress 610 $apentose phosphate pathway 610 $apremalignant 610 $aprimary mouse hepatocytes 610 $aProteomics 610 $arat plasma 610 $areference toxicants 610 $asodium saccharin 610 $astandard operating procedures 610 $asteatosis 610 $atandem mass spectrometry 610 $atissue 610 $atranscription factors 610 $aTranscriptomics 610 $aurine 615 7$aMedicine and Nursing 700 $aWahli$b Walter$4edt$01328658 702 $aGuillou$b Hervé$4edt 702 $aWahli$b Walter$4oth 702 $aGuillou$b Hervé$4oth 906 $aBOOK 912 $a9910557148103321 996 $aMetabolism and Metabolomics of Liver in Health and Disease$93038789 997 $aUNINA